<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FT933-13047</title>
	</head>
	<body>
		<main>
			<p>930721 FT  21 JUL 93 / SmithKline up 18% in quarter SMITHKLINE Beecham, the Anglo-US healthcare group, reported an 18 per cent rise in pre-tax profits for the three months to June 30 to Pounds 294m, from Pounds 249m the previous year. Turnover in the second quarter increased 19 per cent from Pounds 1.26bn to Pounds 1.51bn and the results were flattered by currency gains. Excluding exchange, sales of continuing operations rose 8 per cent and trading profits 10 per cent. The company made an exceptional profit of Pounds 37m on the sale of its hair care products to Wella. The profit from the Dollars 320m (Pounds 212m) disposal of its personal care brands to Sara Lee and a provision for the restructuring of the remaining consumer brands will be made in the third quarter. The pharmaceuticals division reported a 13 per cent rise in trading profits Pounds 157m to Pounds 177m on sales up 22 per cent to Pounds 834m. However, at constant exchange rates sales and trading profits were only 7 per cent and 11 per cent higher. SB said the second quarter last year had been particularly strong. Sales of SB's new products, Paxil, Kytril, Relafen and and Havrix, fell between the first and second quarter this year from Pounds 107m to Pounds 96m. The company blamed destocking in the US after the launch of Paxil earlier this year. Drugs sales in Europe rose only 1 per cent. Growth in the UK and France only partly offset steep declines of 9 per cent and 18 per cent in Germany and Italy, following healthcare reforms. Mr Bob Bauman, chief executive, warned that the healthcare market was becoming more difficult to forecast and the long-term impact of the challenging economic and regulatory environment was not clear. Animal health trading profits increased 22 per cent from Pounds 9m to Pounds 11m on sales up 21 per cent to Pounds 91m. At constant exchange rates sales and trading profits were rose 6 per cent and 20 per cent. Consumer brands operating profits rose 4 per cent from Pounds 34m to Pounds 36m, on turnover up 20 per cent to Pounds 320m. Excluding currency exchange, sales rose 9 per cent and profits were flat. Trading profits at clinical laboratories reported trading profits up 19 per cent from Pounds 19m to at Pounds 22m, on sales up 38 per cent from Pounds 144m to Pounds 201m. Excluding currency exchange, sales were up rose 16 per cent and trading up rose 18 per cent. The figures were flattered by acquisitions. A second quarter dividend was declared of 2.533p per A share, 4.756 cents per equity unit and 23.78 cents per equity unit ADR. Lex, Page 18 Details, Page 20</p>
		</main>
</body></html>
            